Metcela adds Dr. Atsushi Usami and Dr. Hiroaki Kobayashi to Board along with raising $12.7m Series B financing led by Edge Capital Partners

– JAPAN, Kanagawa –  Metcela Inc., a clinical-stage biotech startup specializing in fibroblast-based cell therapy, announced the closing of its 1.3 billion yen ($12.7m) Series B round led by The University of Tokyo Edge Capital Partners, with participation from new and existing investors including Alfresa Corporation, The Dai-ichi Life Insurance Company, MAKOTO Capita, and KSP Inc.…